StockData
Jazz Pharmaceuticals plc logo

Jazz Pharmaceuticals plc (JAZZ) stock

JAZZNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 2, 2026Score 7/30122% above fair value
$240.71+0.94 (+0.39%)

Close on Nov 17, 2026Market cap $15.63BP/E 78.4Yield –

Jazz Pharmaceuticals pe ratio

The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.

Jazz Pharmaceuticals's pe ratio was 17.0× on Nov 11, 2026, against 17.1× a year earlier. Over the last 5 years it ranged from 11.0× to 178.3×, with a median of 18.9×.

PE Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 202617.0×+1.7
2025Jul 31, 202515.3×−2.1
2024Dec 31, 202417.3×−160.9
2023Dec 29, 2023178.3×+38.2
2021Oct 29, 2021140.0×+88.0
2020Dec 31, 202052.1×+37.8
2019Dec 31, 201914.3×−0.4
2018Dec 31, 201814.7×−7.5
2017Dec 29, 201722.2×+3.5
2016Dec 30, 201618.7×−8.3
2015Dec 31, 201527.0×−353.8
2014Dec 31, 2014380.8×+359.4
2013Dec 31, 201321.4×−2.0
2012Dec 31, 201223.5×+9.0
2011Dec 30, 201114.5×–

More Jazz Pharmaceuticals figures

See a number that looks wrong?